Efficacy of lenvatinib in patients with advanced pancreatic (panNETs) and gastrointestinal (giNETs) grade 1/2 (G1/G2) neuroendocrine tumors: results of the international phase II TALENT trial (GETNE 1509)
Authors
Capdevila, JFazio, N
Lopez, C
Teule, A
Valle, Juan W
Tafuto, S
Custodio, A
Reed, N
Raderer, M
Grande, E
Garcia-Carbonero, R
Fonseca, P
Alonso, V
Antonuzzo, L
Spallanzani, A
Berruti, A
Garcia, I
La, Casta A
Hernando, J
Ibrahim, T
Affiliation
Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO) Barcelona, SpainIssue Date
2018
Metadata
Show full item recordCitation
Capdevila J, Fazio N, Lopez C, Teule A, Valle JW, Tafuto S, et al. 1307OEfficacy of lenvatinib in patients with advanced pancreatic (panNETs) and gastrointestinal (giNETs) grade 1/2 (G1/G2) neuroendocrine tumors: results of the international phase II TALENT trial (GETNE 1509). Ann Oncol. 2018;29(suppl_8):467.Journal
Annals of OncologyDOI
10.1093/annonc/mdy293Additional Links
https://dx.doi.org/10.1093/annonc/mdy293Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdy293